S
Saby George
Researcher at Roswell Park Cancer Institute
Publications - 167
Citations - 14398
Saby George is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Nivolumab & Renal cell carcinoma. The author has an hindex of 31, co-authored 138 publications receiving 10182 citations. Previous affiliations of Saby George include Memorial Sloan Kettering Cancer Center & University of Texas Health Science Center at San Antonio.
Papers
More filters
Journal ArticleDOI
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.
Laurence Albiges,Nizar M. Tannir,Mauricio Burotto,David F. McDermott,David F. McDermott,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Thomas Powles,Frede Donskov,Saby George,Christian Kollmannsberger,Howard Gurney,Howard Gurney,Marc-Oliver Grimm,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Toni K. Choueiri,Shruti Shally Saggi,M. Brent McHenry,Robert J. Motzer +21 more
TL;DR: NIVO+IPI continues to demonstrate durable efficacy benefits vs SUN, with manageable safety after long-term follow-up, and safety remained favourable with NIVO-IPI vs SUN.
Journal ArticleDOI
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B. Atkins,Elizabeth R. Plimack,Igor Puzanov,Mayer Fishman,David F. McDermott,Daniel C. Cho,Ulka N. Vaishampayan,Saby George,Thomas Olencki,Jamal Tarazi,Brad Rosbrook,Kathrine C. Fernandez,Mariajose Lechuga,Toni K. Choueiri +13 more
TL;DR: The treatment combination of axitinib plus pembrolizumab is tolerable and shows promising antitumour activity in patients with treatment-naive advanced renal cell carcinoma.
Journal ArticleDOI
Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Therapy
Ali Reza Golshayan,Saby George,D. Y. Heng,Paul Elson,Laura S. Wood,Tarek Mekhail,Jorge A. Garcia,Hakan Aydin,Ming Zhou,Ronald M. Bukowski,Brian I. Rini +10 more
TL;DR: Patients who have mRCC and sarcomatoid differentiation can demonstrate objective responses and tumor shrinkage to VEGF-targeted therapy.
Journal ArticleDOI
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.
Bernard Escudier,Padmanee Sharma,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Howard Gurney,Frede Donskov,K. Peltola,John Wagstaff,Thomas Gauler,Takeshi Ueda,Huanyu Zhao,Ian M. Waxman,Robert J. Motzer +19 more
TL;DR: The trend for OS and ORR benefit with nivolumab for multiple subgroups, without notable safety concerns, may help to guide treatment decisions, and further supports nivorumab as a new standard of care across a broad range of patients with previously treated aRCC.
Journal ArticleDOI
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
Lawrence Fong,Andrew Hotson,John D. Powderly,Mario Sznol,Rebecca S. Heist,Toni K. Choueiri,Saby George,Brett G.M. Hughes,Matthew D. Hellmann,Dale R. Shepard,Brian I. Rini,Shivaani Kummar,Amy Weise,Matthew J. Riese,Ben Markman,Leisha A. Emens,Daruka Mahadevan,Jason J. Luke,Ginna G. Laport,Joshua Brody,Leonel Hernandez-Aya,Philip Bonomi,Jonathan W. Goldman,Lyudmyla Berim,Daniel J. Renouf,Rachel Anne Goodwin,Brian Munneke,Po Y. Ho,Jessica Hsieh,Ian McCaffery,Long Kwei,Stephen Willingham,Richard A. Miller +32 more
TL;DR: A phase 1 clinical trial with a small molecule A2AR antagonist is found that this molecule can safely block adenosine signaling in vivo and represents a targetable immune checkpoint distinct from PD-(L)1 that restricts anti-tumor immunity.